On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- New Target Discovered That Stops Progress of Osteoarthritison January 19, 2021 at 11:08 am
Progress of osteoarthritis can be effectively stopped by injecting a potent EGFR ligand attached to a nanoparticle directly into the knee.
- The race to stop ageing: 10 breakthroughs that will help us grow old healthilyon January 19, 2021 at 1:41 am
The biggest killers in the modern world, like dementia and cancer, are down to ageing. Is it possible to tackle the ageing process so we can live for longer and stay healthier too?
- The Orthopedic Biomaterials Market Size Worth Around US$ 23.10 Billion by 2028on January 18, 2021 at 11:17 am
The Orthopedic Biomaterials Market Size is expected to be worth around US$ 23.10 billion by 2028, Increasing incidence of degenerative joint disease and musculoskeletal disorders is the key factor ...
- New Target Halts Osteoarthritis-type Knee Cartilage Degenerationon January 18, 2021 at 9:27 am
These researchers showed that they could target a specific protein pathway in mice, put it into overdrive and halt cartilage degeneration over time. Building on that finding, they were able to show ...
- Global Orthopaedic Devices Market Forecast Report 2020-2027 - Market is Expected to Reach $53,607.2 Millionon January 18, 2021 at 7:39 am
The market is primarily driven by the increase in incidence and prevalence of musculoskeletal diseases such as osteoarthritis, osteoporosis, spinal degenerative diseases ... demineralized bone matrix, ...
- Target discovered that halts osteoarthritis-type knee cartilage degenerationon January 17, 2021 at 8:01 pm
When mice were injected with these nanotherapeutics, the researchers saw that they slowed cartilage degeneration and bone hardening ... "There is a great unmet medical need for a disease-modifying ...
- Scientists discover new treatment target for osteoarthritis-like knee cartilage degenerationon January 16, 2021 at 4:51 pm
There is currently no cure for osteoarthritis, but a group of scientists believe they've discovered a method through which a simple knee injection could potentially stop the disease's effects.
- Orthopaedic Devices Global Market - Forecast to 2027on January 14, 2021 at 1:05 am
Reportlinker.com announces the release of the report "Orthopaedic Devices Global Market - Forecast to 2027" - As a result of rapid advances, there is great expansion in the potential therapeutic ...
- Small Treatment with Big Effect: Using the Space Station to Understand How Nanoparticles Could Combat Bone Losson January 13, 2021 at 4:00 pm
In 2015, a team led by three Italian scientists sent an experiment to the International Space Station to be performed by ESA (European Space Agency) astronaut, Samantha Cristoforetti, who is Italian.
via Bing News